OVERVIEW

Join us in Indianapolis for a full day of presentations by the nation’s top experts in hematology and hematology malignancies. Participants will have the opportunity to interact with these thought leaders in several panel discussions. This annual hematology review is one of the most comprehensive, educational hematology conferences in the country. Our exceptional faculty will provide a concise and practical summary of the American Society of Hematology annual meeting, presenting the most current hematology research and clinical practice.

The Indy Hematology Review™ annually offers an essential and up-to-date educational and scientific meeting for hematology professionals. Participate in the Review to hear a summary from leading hematology researchers and educators as they discuss the most recent developments to improve patient management and care. Data from major hematology and oncology conferences of the past year, including the American Society of Hematology, American Society of Clinical Oncology and the European Hematology Association Congress will be reviewed in a fast-paced format that includes Q&A.

The Indy Hematology Review™ brings together over 300 hematologists, oncologists, radiologists, physician assistants, oncology RN’s, nurse practitioners, pharmacists, medical students, and other allied health professionals to examine significant scientific updates in clinical hematologic research, learn how these updates directly affect the study and practice of hematology, and discover how new research can be translated into new patient care strategies.

LEARNING OBJECTIVES

1. Improve patient outcomes by incorporating the most current therapies for Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
2. Explain how Apollo and the Indianapolis Oracle will impact the treatment of Myelodysplastic Syndromes.
3. Predict the future of Chronic Myeloid Leukemia and how it might impact patient care strategies.
4. Identify the emerging treatment options for Multiple Myeloma and describe how to put these treatment options into practice.
5. Review the most current and evolving treatment options for Waldenstrom’s Macroglobulinemia
6. Adjust their treatment strategies for patients with Amyloidosis to include emerging therapies as appropriate
7. Evaluate the diagnosis for cellular blood disorders including how best to treat disorders such as Polycythemia Vera and Essential Thrombocytosis.
8. Discuss the most current research for the diagnosis and treatment of Myelofibrosis, Philadelphia Chromosome Negative MPN’s and FGFR Mutant Myeloid Neoplasms
9. Improve the management of benign hematology consultations and treatment options for Coagulopathy, Cytosis and Cytopenias in practice
10. Describe the current controversies and updated treatment recommendations for patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
11. Choose the appropriate therapy or therapies for patients with Chronic Lymphocytic Leukemia.
12. Devise a treatment strategy that may improve outcomes for patients with Aggressive B and T Cell Lymphomas
13. Identify when Hematopoietic Transplantation and Cellular Therapies are an appropriate treatment strategy

ACCREDITATION

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University College of Pharmacy designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)™. Symposium – 8:00 am – 7:00 pm. Purdue University College of Pharmacy designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ (Town Hall Interactive Meeting – 7:30 – 8:45 pm). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.